Business of Biosimilars & Generic Drugs Session Spotlight: When Being the Same is Good Enough: Building Public Confidence and Interest in Biosimilars

There’s an enormous amount of public confusion and misconceptions about the efficacy and safety of biosimilars, even in markets such as Europe where these products are already available. By anticipating and countering the public’s fears you can assure better product uptake.  Today we feature the session "When Being the Same is Good Enough: Building Public Confidence and Interest in Biosimilars," presented by Alex Bruni, VP for Commercial Operations, Merz Pharmaceuticals.

Alex Bruni

The Business of Biosimilars and Generic Drugs will take place September 10-12, 2012 in Boston, MA.  For more information on the rest of the program, download the agenda.  If you'd like to join us in Boston, register today and mention code XP1786BLOG to save 25% off the standard rate!

Featured Session: When Being the Same is Good Enough: Building Public Confidence and Interest in Biosimilars
Featured Speaker: Alex Bruni, VP for Commercial Operations, Merz Pharmaceuticals
About the Session: Even as small-molecule generics have grown to take the majority of the prescription market, there are still widespread misconceptions and apprehensions about their quality and effectiveness. Biosimilars have yet to prove themselves in the U.S. market, but they will surely face the same public scrutiny and “urban legends.” How can you best confront counter-messaging and position your product as the best in its class?

Share this article with your social network, just click below to share now!

Share |